



MARYLAND  
**MMCC**

Natalie M. LaPrade  
Maryland Medical Cannabis Commission

**Maryland Medical Cannabis Commission  
Committee Meeting  
Thursday, December 14, 2017-2:00 pm  
Legislative Services Building Joint Hearing Room, 1<sup>st</sup> Floor  
90 State Circle, Annapolis, MD 21401**

## **MINUTES**

### **Commissioners Present**

Brian Lopez, MMCC Chairman  
Charles Smith, Policy Committee Chair  
Charles LoDico  
Tiffany Randolph

### **Commissioners Absent**

Barry Pope  
Rachel Rhodes

### **MMCC Staff Present**

Joy A. Strand, Executive Director  
Lori Dodson, Deputy Director  
David Kloos, Director of Enforcement and Compliance  
Heather Nelson, Assistant Attorney General  
Mary-jo Mather, Director of Administration  
Myesha McQueen, Administrative Specialist  
Kristen Shreves, QA Specialist

### **Welcome and Call to Order**

Commissioner Smith welcomed the attendees and called the meeting to order at 12:45 pm. He introduced the Commission's new Executive Director, Joy A. Strand, MHA. Ms. Strand expressed her pleasure to serve and informed attendees that she will devote all her energy toward the Commission's mission to serve patients who need this medical treatment. Chairman Smith also introduced the newly-appointed Commissioner, Tiffany Randolph, who also expressed her pleasure to serve and her eagerness to make a contribution to the Commission's work.

### **Approval of Minutes**

The Policy Committee Minutes from the October 23, 2017 meeting were unanimously approved, after motions offered by Commissioner Lopez and Commissioner LoDico.

### **Proposed Changes to the Regulations**

Chairman Smith reported that the Policy Committee had heard oral comment and received extensive written comments on the subject of out-of-state patients at previous meetings. He noted that the Committee awaits more information on the legislative intent on this topic, and accordingly, no proposed language would not be voted on at this meeting. The Committee will not accept any further comment at this time on this issue. Chairman Smith reported that all out-of-state patient applications received will continue to be on administrative hold.

Chairman Smith asked Executive Director to present the staff's recommendation for new language in the regulations regarding stability testing and sample retention. Ms. Strand announced that new language regarding stability testing will be presented after further research is completed.

#### **Proposed New Language for COMAR 10.62.15.07**

- A. Retention samples returned from each batch shall:
- (1) Sufficiently provide for testing by a registered Independent Testing Laboratory other than the original certifying laboratory following an adverse event reported to the Commission;
  - (2) Be properly stored by the licensed Grower;
  - (3) Be properly discarded six months after the expiration date of the batch.

There was no further discussion. A motion to approve this new language was offered by Chairman Lopez, and seconded by Commissioner LoDico. The motion passed unanimously.

#### **Proposed New Language for 10.62.23.06**

- A. Retention samples retained from each released lot shall:
- (1) Sufficiently provide for testing by a registered independent testing laboratory other than the original certifying laboratory following an adverse event reported to the Commission;
  - (2) Be properly stored by the licensed processor; and
  - (3) Be properly discarded six months after the expiration date of the lot.

There was no further discussion. A motion to approve this new language was offered by Chairman Lopez, and seconded by Commissioner LoDico. The motion passed unanimously.

Chairman Smith noted that Commissioner Abdeshahian suggested that public comment be requested for presentation at the next Policy Committee meeting on the following topics:

- 1) Clinical Director requirement for Dispensaries;
- 2) CRISP as a repository for medical-cannabis patient information and medical information in regard to cannabis amounts and modalities dispensed;
- 3) Defining the frequency of follow-up for medical cannabis patients by the patients' registered medical providers
- 4) Defining the scope of practice for authorized medical cannabis providers (Physicians, Dentists, Podiatrists, Nurse Practitioners and Midwives) for recommending medical cannabis; and
- 5) Adding the requirement (at Dispensary point-of-sale) to collect key clinical data regarding the use of medical cannabis.

**New Business**

There was no new business.

**Adjournment**

Chairman Smith adjourned the meeting at 12:55 pm.